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The biochemicalmechanisms that underlie hypoxia-inducedNF-kBactivity have remained largely undefined.
Here, we find that prolonged hypoxia-induced NF-kB activation is restricted to cancer cell lines infected with
high-risk human papillomavirus (HPV) serotypes. The HPV-encoded E6 protein is necessary and sufficient for
prolonged hypoxia-induced NF-kB activation in these systems. Themolecular target of E6 in the NF-kBpath-
way is the CYLD lysine 63 (K63) deubiquitinase, a negative regulator of the NF-kB pathway. Specifically, hyp-
oxia stimulates E6-mediated ubiquitination and proteasomal degradation of CYLD.Given the established role
of NF-kB in human carcinogenesis, these findings provide a potential molecular/viral link between hypoxia
and the adverse clinical outcomes observed in HPV-associated malignancies.
INTRODUCTION
It has been over 50 years since the seminal observation by
Thomlinson and Gray that intratumoral hypoxia is associated
with resistance to radiation therapy (Thomlinson and Gray,
1955). In the ensuing decades, mounting clinical and experimen-
tal evidence has established the influence of hypoxia on tumor
biology. For example, the identification of intratumoral hypoxia
in patients with cervical and head and neck cancer is associated
with an increased risk for local recurrence after radiation, the
presence of lymphatic and hematogenous metastases, and re-
duced overall survival (Tatum et al., 2006). Moreover, hypoxia
is associated with resistance to not only radiation therapy but
also cytotoxic chemotherapy (Harris, 2002; Le et al., 2004; Sub-
arsky and Hill, 2003). Additional investigations have further ex-
tended the importance of hypoxia in the malignant progression
of other tumor models, such as sarcomas, breast cancer, and
prostate cancer (Tatum et al., 2006; Vaupel et al., 2001, 2002).
As a solid tumor grows, hypoxia invariably occurs as a conse-
quence of aberrant neoangiogenesis, cancer-associated anemia
that results in reduced oxygen-carrying capacity of blood, in-
creased oxygen demand of the growing tumor, and abnormal ox-
ygen diffusion due to imbalances in directional microcirculation
(Hockel and Vaupel, 2001). In addition to reduced oxygen tension,
the hypoxic environment is also characterized by acidosis and di-
minished micronutrient availability. Thus, during carcinogenesis,
premalignant and malignant cells must adapt to the harsh hyp-
oxic microenvironment and do so through both genomic and non-
genomic mechanisms (Hockel and Vaupel, 2001). Indeed, hyp-
oxia results in genomic instability manifested by increased rates
of gene amplification, point mutation, and chromosomal rear-
rangement that add to the genomic complexity of tumor cells
(Hockel and Vaupel, 2001; Reynolds et al., 1996; Young et al.,
1988). Through selection pressures, this genomic instability leads
to outgrowth of clones that manifest survival and even prolifera-
tion advantages as well as resistance to antineoplastic therapy.
SIGNIFICANCE
Intratumoral hypoxia is a critical factor in the poor clinical outcomes of humanmalignancies, most notably cervical and head
and neck cancers. Here, we find that prolonged hypoxia-induced NF-kB activation is not a generalized phenomenon among
cancer cells but rather is restricted to human papillomavirus (HPV)-positive cancers, such as cervical and head and neck
cancers. Under hypoxic conditions, the HPV-encoded E6 protein inactivates the CYLD tumor suppressor, a negative reg-
ulator of the NF-kB pathway, and thereby allows for unrestricted activation of NF-kB. Because NF-kB-induced genes pro-
mote survival, proliferation, and angiogenesis, our findings illustrate how a common human virus adapts to hypoxia and
helps account for the aggressive tumor biology associated with hypoxia.394 Cancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc.
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thoroughly studied and include upregulation of angiogenesis,
oxygen transport, glycolysis, and glucose uptake (Harris,
2002). Many of these adaptations are mediated by the transcrip-
tion factor hypoxia-inducible factor alpha (HIFa), which drives
expression of hypoxia-response genes, such as vascular endo-
thelial growth factor (VEGF). In addition to HIFa, other transcrip-
tion factors have been reported to be activated by hypoxia. For
example, hypoxia-induced activation of the NF-kB family of tran-
scription factors has been observed in some tumor models
(Koong et al., 1994; Royds et al., 1998). NF-kB is a family of tran-
scription factors that induce a transcriptional response that re-
sults in the expression of proteins that promote survival, prolifer-
ation, angiogenesis, invasion, and metastasis (Baldwin, 2001).
Accordingly, hypoxia-induced NF-kB activation represents an-
other potential mechanism whereby tumor cells could adapt to
the inhospitable hypoxic milieu.
Whereas constitutive NF-kB activity has been implicated in the
malignant progression of numerous hematologic and solid ma-
lignancies (Basseres and Baldwin, 2006), a comprehensive anal-
ysis of the timing and duration of hypoxia-induced NF-kB activa-
tion has not been performed to our knowledge. Moreover, the
biochemical mechanisms that underlie hypoxia-induced NF-kB
activity have remained largely undefined. In the current study,
we observed that prolonged hypoxia-induced NF-kB activation
was restricted to human papillomavirus (HPV)-positive cancer
cells and was mediated by an effect of the HPV-encoded E6 pro-
tein on polyubiquitination and subsequent degradation of the
CYLD lysine 63 (K63) deubiquitinase.
RESULTS
Prolonged Hypoxia-Induced NF-kB Activation
Is Restricted to HPV-Infected Cell Types
Although hypoxia-induced NF-kB activation has been reported
in various cell systems, a thorough analysis of the timing and ex-
tent of hypoxia-induced NF-kB activation across a wide range of
malignant cell types has not been performed. We performed
electrophoretic mobility shift assays (EMSAs) to screen 32 hu-
man cancer cell lines of epithelial or mesenchymal origin for hyp-
oxia-induced (1% O2) NF-kB activation. Only 4 of 32 cell lines ex-
hibited hypoxia-induced NF-kB activation at 24 or 48 hr time
points, and all four of these cell lines represented squamous
cell carcinomas of the cervix (HeLa, SiHa, and Me180; n = 3) or
head and neck (HEp2; n = 1), all of which are infected with
high-risk HPV serotypes (Figure 1A; see also Table S1 available
online). Strikingly, in HPV-negative cervical (HT3 and C33A) and
head and neck (CAL27) cancer cell lines, hypoxia resulted in ei-
ther no change or a decrease in NF-kB activity (Figure 1A; Table
S1). These results were confirmed by transient transfection of an
NF-kB-driven reporter (Figure 1B; Table S1). Electrophoretic
mobility supershift analyses revealed that the NF-kB complexes
were composed of p65 and p50, components of the classical
NF-kB pathway (Figure 1C). Of note, the p65 antibody employed
for this assay did not retard the migration of the band represent-
ing p65-p50 heterodimers but rather prevented p65-p50 hetero-
dimers from binding to the radiolabeled NF-kB oligonucleotide
probe and therefore resulted in a reduced signal attributable to
p65-p50 DNA binding (Lee and Ziegler, 2007).CWe evaluated HPV-positive and -negative tumor xenografts
for hypoxia-induced NF-kB activation. HeLa (HPV18-positive
squamous cell carcinoma of the cervix) and CAL27 (HPV-nega-
tive squamous cell carcinoma of the head and neck) subcutane-
ous xenografts were harvested from the flanks of nude mice 1 hr
after intraperitoneal injection of the hypoxia marker pimonida-
zole. In HeLa xenografts, regions of hypoxia as detected by
pimonidazole staining were associated with nuclear p65 stain-
ing, whereas relatively nonhypoxic regions manifested predom-
inantly cytoplasmic p65 expression (Figure S1A). We did not
observe any nonspecific staining by a control antibody of the
same isotype (rabbit IgG) as the p65 antibody (data not shown).
In contrast, p65 nuclear staining was actually reduced in hypoxic
regions in CAL27 xenografts (Figure S1B), a result concordant
with the diminished NF-kB activation observed in CAL27 cells
in vitro (Figure 1A).
A detailed time-course analysis of HPV-positive HeLa and
SiHa (HPV serotype 16) cells revealed that hypoxia-induced
NF-kB activation occurred rapidly (i.e., within 15 min) and was
sustained for at least 48 hr (Figure 1D, top panels). Hypoxia did
not affect the electrophoretic mobility of AP1 or Oct-1 com-
plexes (Figures 1D and 1E), indicating that hypoxia-induced tran-
scription factor activation is not a generalized phenomenon.
When hypoxic HPV-positive cells were returned to normoxia
(21% O2), NF-kB levels gradually declined (Figure 1E). Specifi-
cally, NF-kB activity was maintained for several hours prior to
a return to the baseline level of NF-kB activity exhibited at nor-
moxia prior to initial exposure to hypoxic conditions. Some
HPV-negative cell lines exhibited a modest degree of transient
hypoxia-induced NF-kB activation that abated after 3 hr
(Figure 1F). For example, DLD-1 cells, an HPV-negative colon
cancer cell line, exhibited activation of NF-kB after 1 and 3 hr
of hypoxia exposure, but at later time points, cells no longer
demonstrated heightened NF-kB activity. Taken together, these
data indicate that prolonged hypoxia-induced NF-kB activation
is restricted to HPV-positive cancer cell models.
Activation of NF-kB is typically mediated by biochemical sig-
naling events that converge on the IkB kinase (IKK) complex,
which consists of the IKKg (NEMO), IKKa, and IKKb isoforms
(Karin, 2006; Chen, 2005). Whereas IKKg is the essential regula-
tory unit of the IKK complex, IKKa and IKKb are catalytic sub-
units that are operative in the alternative and classical NF-kB
pathways, respectively, and mediate NF-kB activation by phos-
phorylating IkB inhibitory proteins, thereby targeting IkB for ubiq-
uitination and subsequent proteasomal degradation. Because
our electrophoretic mobility supershift experiments indicated
that hypoxia-induced NF-kB activation involved members of the
classical NF-kB pathway, we evaluated the effects of hypoxia on
IKKb activity. Prolonged hypoxia (24 hr) induced IKKb kinase
activity in HeLa and SiHa cells (Figure S2A). We also investigated
the timing of IKKb activation in HPV-positive and -negative cell
models. In HPV-positive cells (HeLa and SiHa), hypoxia-induced
IKKb activation occurred rapidly and was sustained (Figure S2B,
top panels). In contrast, in HPV-negative cells, hypoxia either
failed to induce IKKb altogether (C33A) or resulted in transient
IKKb activation at 1 hr that returned to baseline levels after 4 hr
(HT3 and DLD-1 colon cancer cells; Figure S2B, bottom panels).
The timing of IKKb activation correlated with the timing of NF-kB
activation observed in the gel shift assays (Figures 1D and 1F)ancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc. 395
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prolonged hypoxia-induced activation of the NF-kB pathway is
restricted to HPV-positive tumor cells.
HPV E6 Protein Is Necessary and Sufficient
for Prolonged Hypoxia-Induced NF-kB Activation
Next, we explored the hypothesis that an HPV-encoded protein
mediates prolonged hypoxia-induced NF-kB activation. Only
two HPV-encoded proteins, E6 and E7, are expressed in HPV-
positive squamous cell carcinomas (Munger et al., 2004). The
E6 and E7 proteins inactivate and inhibit the expression of the
p53 and pRB tumor suppressor proteins, respectively, although
p53- and pRB-independent oncogenic functions of these HPV-
Figure 1. Effects of Hypoxia and Reoxyge-
nation on NF-kB Activation
(A) Representative EMSAs for measurement of
NF-kB activity under normoxic (21% O2) and hyp-
oxic (1% O2) conditions for the indicated times.
WT and M, cold competition with 100-fold molar
excess of wild-type and mutant NF-kB DNA re-
sponse elements, respectively. Red, HPV-positive
squamous cell carcinoma; blue, HPV-negative
squamous cell carcinoma; black, nonsquamous
cell carcinoma.
(B) NF-kB reporter assays performed 48 hr after
transfection. N, normoxia; H, hypoxia. Results
are averages of three experiments ± standard de-
viation (SD). Firefly luciferase expression was nor-
malized to that of Renilla luciferase (see Supple-
mental Experimental Procedures). RLU, relative
luciferase units.
(C) Electrophoretic mobility supershift assays
were performed with the indicated antibodies after
cells were exposed to hypoxia for 24 hr.
(D) Top row: EMSAs demonstrate detailed time
course of hypoxia-induced NF-kB activity. Sec-
ond row: Oct-1 EMSAs serve as a control. Third
row: HIF1a western blots confirm exposure to
hypoxia. Bottom row: g-tubulin western blots as
loading controls.
(E) Effects of reoxygenation on NF-kB activity,
measured by EMSA. EMSAs for AP1 or Oct-1
served as controls. Cells were exposed to hypoxia
for 24 hr, followed by return to normoxic condi-
tions (reoxygenation) for the indicated times.
(F) Transient hypoxia-induced NF-kB activation in
HPV-negative cancer cells. Top two rows: shorter-
course hypoxia exposure (1 hr) of HPV-negative
cancer cells. Bottom row: detailed time course of
transient NF-kB activation.
encoded proteins have been well docu-
mented (Munger et al., 2004; Scheffner
and Whitaker, 2003). To investigate the
effects of E6 and E7 on hypoxia-induced
NF-kB activation, we performed RNA in-
terference (RNAi) with small interfering
RNAs (siRNAs) to silence expression of
the E6 and E7 proteins in HeLa cells. Be-
cause E6 and E7 are expressed as a bicis-
tronic transcript, RNAi that is specific for
either E6 or E7 has variably been reported
to silence expression of one or both of the proteins (Butz et al.,
2003; Favre-Bonvin et al., 2005; Jiang and Milner, 2002). E6
siRNA selectively induced p53 expression in HeLa cells (E6 can-
not be detected by direct immunoblotting, so p53 expression
serves as a surrogate for E6 expression; Figure 2A, middle set
of panels) but did not alter E7 or pRB levels (Figure 2A, panels
on right and second from left). Scrambled control siRNAs had
no effect on E6 or E7 expression. Silencing of E6 was associated
with inhibition of hypoxia-induced NF-kB activation as well as
reduction in the constitutive NF-kB activity observed at nor-
moxia, whereas control siRNA did not affect NF-kB activity (Fig-
ures 2B and 2C). The finding of increased NF-kB activity in E6-si-
lenced hypoxic versus normoxic cells suggests the possibility of396 Cancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc.
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of the prolonged hypoxia-induced NF-kB activation observed
in HPV-positive cells. Similar results were obtained for E6 silenc-
ing in SiHa cells (Figure S3). To further demonstrate specificity
of the effects of E6 siRNA for HPV-positive cells, we demon-
strated that E6 siRNA did not influence constitutive or transient
hypoxia-induced NF-kB activation observed in HPV-negative
DLD-1 cells (Figure S4). RNAi-based silencing of E7 expression
in HeLa cells also resulted in a decrease in hypoxia-induced
and constitutive NF-kB activation (Figures 2B and 2C). However,
we cannot attribute this effect to loss of E7 expression, because
E7 RNAi led not only to reduction in E7 levels with an associated
increase in pRB expression but also to silencing of E6 expression
(Figure 2A).
To further explore the role of E6 and E7 in mediating hypoxia-
induced NF-kB activation, we expressed HPV16 E6 or E6 plus
increasing amounts of E7 in C33A cells. Whereas ectopic ex-
pression of E6 resulted in a dose-dependent increase in hyp-
oxia-induced NF-kB activation in C33A cells, E7 did not augment
this response (Figure 2D), nor did it have any effect on its own
(data not shown). In addition, coexpression of E7 with E6 did
not enhance the E6-mediated effects on NF-kB activation
(Figure 2E). We obtained similar results in HEK293 cells (human
embryonic kidney cells that are HPV negative), although experi-
ments in HEK293 cells were performed only under normoxia be-
cause prolonged hypoxia induced massive cell death (Figures 2F
and 2G). Because squamous cell carcinomas arise from the ma-
lignant transformation of keratinocytes, we examined the effects
of ectopic expression of E6 or E7 introduced by retroviral trans-
duction into human keratinocytes. Similar to our results in
HEK293 and C33A cells, E6, but not E7, expression in human
keratinocytes resulted in activation of NF-kB under hypoxic con-
ditions (Figure 2H). We next tested whether activation of IKKb
under hypoxic conditions was dependent upon E6 expression.
Indeed, hypoxia-induced IKKb activation in HPV-positive cells
was negated by silencing E6 protein expression with E6-specific
siRNA (Figure 2I), thereby establishing that E6-mediated regula-
tion of hypoxia-induced NF-kB activation involves activation of
IKKb. Based on these gene transfer experiments combined
with the results of the RNA interference studies, we conclude
that the HPV E6 protein is necessary and sufficient for prolonged
hypoxia-induced NF-kB activation in HPV-positive cells.
Figure 2. HPV E6 Is Necessary and Suffi-
cient for Prolonged Hypoxia-Induced
NF-kB Activation
(A) Western blots for E7, p53, and pRB (a surrogate
for E7 expression). Cells were transfected with the
indicated siRNAs, and immunoblotting was per-
formed with the indicated antibodies after 48 hr.
C, scrambled control siRNA.
(B) EMSAs showing the effects of E7 and E6 RNAi
on NF-kB activity.
(C) Same as in (B), but NF-kB activity was mea-
sured by reporter assay performed under hypoxic
conditions. Results were normalized to that of the
scrambled control siRNA.
(D) NF-kB reporter activity due to transfection of
HPV16 E6 under hypoxic conditions. Cells were
exposed to normoxia or hypoxia for 48 hr, and re-
sults are represented as the ratio of NF-kB re-
porter activity in hypoxia to normoxia.
(E) NF-kB reporter activity resulting from transfec-
tion of E6 plus increasing concentrations of E7.
Results were calculated as in (D).
(F) NF-kB reporter activity resulting from transfec-
tion of HPV16 E6 or E7.
(G) NF-kB reporter activity resulting from transfec-
tion of E6 plus increasing amounts of E7. Data in
(C)–(G) are presented as averages of three exper-
iments ± SD. In (D)–(G), results were normalized to
those of vector controls, and firefly luciferase ex-
pression was normalized to that of Renilla lucifer-
ase (see Supplemental Experimental Procedures).
(H) EMSAs in primary murine keratinocytes stably
transduced with control, E6, or E7 retroviral
vectors.
(I) IKKb in vitro kinase assays (top two rows) were
performed on extracts exposed to normoxia or
hypoxia. Successful silencing of E6 is shown in
the bottom two panels.Cancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc. 397
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Hypoxia-Induced NF-kB ActivationFigure 3. Hypoxia Induces TRAF6Ubiquitination in anE6-Dependent
Fashion
(A) Cells were cotransfected with a dominant-negative TRAF6 (TRAF6-DN) or
a control expression plasmid plus the NF-kB luciferase reporter. Results are
means of three experiments ± SD and are represented as the ratio of NF-kB
reporter activity in hypoxia to normoxia (48 hr). Firefly luciferase expression
was normalized to that of Renilla luciferase (see Supplemental Experimental
Procedures).
(B) Hypoxia-induced TRAF6 polyubiquitination. TRAF6 immunoprecipitates
were immunoblotted with ubiquitin (top) or TRAF6 (bottom) antibodies.
(C) TRAF6 polyubiquitination in normoxia and hypoxia (1 hr).398 Cancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier IncGiven the importance of HIFa in cellular adaptation to hypoxia,
we also sought to determine whether HIFa plays a role in
prolonged hypoxia-induced NF-kB activation. Toward this end,
we silenced expression of HIFa in HeLa and SiHa cells
(Figure S5A). Downregulation of HIF1a protein levels (HIF1a, as
opposed to HIF2a, is the predominant isoform expressed in
HeLa and SiHa cells) by HIF1a-specific siRNA had no effect on
hypoxia-induced NF-kB activation (Figure S5B), indicating that
the effects of hypoxia on NF-kB occur in a HIFa-independent
fashion.
In HPV-Positive Cells, Hypoxia-Induced NF-kB
Activation Is TRAF6 Dependent and Hypoxia-Induced
TRAF6 Polyubiquitination Is E6 Dependent
In response to activation of cell-surface receptors, including
members of the tumor necrosis factor (TNF) receptor superfam-
ily, Toll-like receptors, and the interleukin-1 receptor, the TNF re-
ceptor-associated factors (TRAFs) activate the IKK complex
(Chen, 2005). We focused on TRAF6 (one of seven TRAF family
members), which in combination with a trimeric protein complex
consisting of TGFb-activated kinase (TAK1) and TAK1-binding
proteins 1 and 2 activates the IKKb/IKKg complex (Chen,
2005). Transfection of a TRAF6 dominant-negative expression
plasmid into HeLa or SiHa cells inhibited hypoxia-induced NF-
kB activation in a dose-dependent fashion (Figure 3A). When
TRAF6 receives upstream signals from cell-surface receptors,
it oligomerizes and transautoubiquitinates, a process that results
in lysine 63 (K63)-linked polyubiquitination of TRAF6 (Chen,
2005; Wang et al., 2001). In contrast to K48 polyubiquitination,
which results in proteasome-mediated degradation of ubiquiti-
nated proteins, K63 polyubiquitination is a proteasome-indepen-
dent activating event in the NF-kB pathway (Krappmann and
Scheidereit, 2005). In HeLa and SiHa cells exposed to hypoxia,
TRAF6 polyubiquitination increased (Figure 3B). Hypoxia-in-
duced TRAF6 polyubiquitination was not observed in HPV-neg-
ative DLD-1 cells (Figure 3C). Moreover, hypoxia-induced TRAF6
polyubiquitination was prevented by gene silencing of E6 ex-
pression with E6-specific siRNA (Figure 3D). Although these re-
sults indicate that E6 mediates hypoxia-induced NF-kB activa-
tion through a TRAF6-dependent mechanism, we rejected the
possibility that TRAF6 is the direct molecular target of E6 within
the NF-kB signaling pathway based on the following rationale.
E6-Mediated Activation of NF-kB under Hypoxia
Is Dependent upon CYLD
HPV-encoded E6 recruits p53 to a protein complex in which the
cellular protein E6-associated protein (E6-AP) polyubiquitinates
p53 through K48 linkages and thereby targets p53 for protea-
some-dependent degradation (Munger et al., 2004). Because
E6 functions in the context of a K48 ubiquitin ligase complex
and TRAF6 activation occurs as a consequence of K63 polyubi-
quitination, it did not seem plausible that E6 is involved in both
K48 and a K63 ubiquitin ligase activity. Along these lines, there
are two K63 deubiquitinases, A20 and CYLD, which function to
(D) TRAF6 polyubiquitination was assessed as in (B), but after transfection of
control or E6 siRNA. All immunoprecipitations were performed under denatur-
ing conditions..
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TRAF2, TRAF6, and IKKg) in the NF-kB pathway and conse-
quently inactivate these signaling proteins, thereby providing
negative feedback signals to the NF-kB pathway (Chen, 2005).
We concentrated on CYLD because the CYLD deubiquitinase
is operative in keratinocytes (Massoumi et al., 2006), the cells
from which squamous cell carcinomas originate.
We determined whether CYLD expression was required for
hypoxia-inducible activation of NF-kB in various cell models
with endogenous or ectopic expression of E6. When we silenced
CYLD expression in HeLa and SiHa cells with CYLD-specific
siRNA (Figure 4A), hypoxia-induced NF-kB activation as mea-
sured by reporter assay was markedly reduced compared to
control siRNA (Figure 4B). Similar results were obtained in
C33A cells transiently transfected with E6 (Figures 4C and
4D)—that is, inhibition of endogenous CYLD expression by
CYLD siRNA in C33A cells (Figure 4C) abrogated the hypoxia-in-
duced NF-kB activation associated with ectopic E6 expression
(Figure 4D).
Figure 4. E6-Mediated Activation of NF-kB Is Depen-
dent upon CYLD
(A) Western blots for CYLD in cells transfected with CYLD or
scrambled control siRNA.
(B) Effects of CYLD RNAi on hypoxia-induced NF-kB reporter
activity. Results are reported as the ratio of NF-kB activity in
hypoxia to normoxia.
(C) Cells were transfected with an HPV16 E6 expression vector
and control or E6-specific siRNA. Protein was harvested at
48 hr. Western blots for CYLD and actin demonstrate effective
silencing of CYLD.
(D) Effects of CYLD RNAi on hypoxia-induced NF-kB reporter
activity. Results are reported as the ratio of NF-kB activity in
hypoxia to normoxia.
(E) Effects of CYLD RNAi on hypoxia-induced NF-kB activity
as measured by EMSA. Top row: NF-kB EMSA. Bottom row:
Oct-1 EMSA.
(F) Ratio of NF-kB reporter activity (hypoxia/normoxia) in pri-
mary wild-type (CYLD+/+) or CYLD knockout (CYLD/) pri-
mary epidermal keratinocytes transfected with HPV16 E6 or
vector control plasmid. Results in (B), (D), and (F) are averages
of three experiments ± SD. Duration of hypoxia was 24 hr.
(G) Effects of E6 expression on NF-kB activation in CYLD+/+ or
CYLD/ primary epidermal keratinocytes assayed by EMSA.
C, lentiviral control transduction; E6, HA-E6 lentiviral trans-
duction; N, normoxia; H, hypoxia for 12 hr.
When we performed this experiment in HeLa
cells with an EMSA as the readout, we again found
that cells treated with control siRNA manifested
hypoxia-induced NF-kB activation (Figure 4E). Im-
portantly, CYLD silencing resulted in heightened
NF-kB activation under normoxic conditions to
a degree that approximated that of the hypoxia-in-
duced NF-kB activation in control siRNA-treated
cells (Figure 4E), suggesting that abrogation of
CYLD expression in HPV-positive cells is sufficient
to recapitulate prolonged hypoxia-induced NF-kB
activation. A low level of residual hypoxia-induced
NF-kB activation was observed in CYLD siRNA-
treated HeLa cells and may have been attributable
to incomplete silencing of CYLD expression (Figure 4E, compare
lane 2 to lane 4). Thus, induction of NF-kB activity by hypoxia oc-
curred only in the setting of CYLD expression. NF-kB activation
induced by TNFa was greater than that observed in normoxic
conditions in CYLD siRNA-treated cells (Figure 4E, compare
lane 6 to lane 2). Thus, the absence of significant hypoxia-
induced NF-kB activation in CYLD siRNA-treated cells was not
attributable to a hypothetical limit in the level of NF-kB activation
in HeLa cells.
To more fully characterize the role of CYLD in mediating E6 ef-
fects on NF-kB, we studied hypoxia-induced NF-kB activation in
CYLD-deficient (CYLD/) and wild-type (CYLD+/+) murine kera-
tinocytes transiently transfected with E6 or a vector control. In
the absence of E6 expression (vector control transfection), hyp-
oxia-induced NF-kB reporter activation was not observed in
either CYLD/ or CYLD+/+ keratinocytes (Figure 4F). E6 trans-
fection into CYLD+/+ keratinocytes resulted in hypoxia-induced
NF-kB activation, whereas NF-kB inducibility under hypoxic
conditions was lost in CYLD/ keratinocytes despite ectopicCancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc. 399
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data, we analyzed NF-kB activation by EMSA in CYLD/ and
CYLD+/+ keratinocytes with or without ectopic expression of
HPV16 E6. These studies required high transfection efficiency
of E6. Accordingly, we cloned an HA-tagged version of HPV16
E6 into a lentiviral vector in which green fluorescent protein
(GFP) is coexpressed downstream of the EMCV internal ribo-
some entry site. One hundred percent of lentivirally transduced
CYLD/ and CYLD+/+ keratinocytes exhibited green fluores-
cence under UV microscopy (data not shown), and functional
expression of E6 was documented by downregulation of p53 ex-
pression (Figure 4G, top panels). In the setting of E6 expression,
hypoxia induced marked activation of NF-kB in CYLD+/+, but not
in CYLD/, keratinocytes (Figure 4G, lanes 2, 4, 6, and 8). In the
absence of E6, very little or no hypoxia-induced NF-kB activation
was observed in either CYLD/ or CYLD+/+ keratinocytes
(Figure 4G, lanes 1, 3, 5, and 7). A slight increase in the intensity
of the NF-kB gel-shifted band in control-transduced CYLD+/+
cells under hypoxia is likely an artifact of unequal protein loading,
as the gel-shifted band for Oct-1 was also increased under these
conditions (Figure 4 G, compare lane 1 to lane 5). Interestingly,
constitutive NF-kB activation under normoxic conditions was
not significantly different in CYLD/ and CYLD+/+ keratinocytes
transduced with control lentivirus, a finding supported by a previ-
ous report (Massoumi et al., 2006). In summary, these data in
murine keratinocytes in combination with the CYLD siRNA ex-
periments in HeLa and SiHa cells demonstrate that E6 mediation
of hypoxia-induced NF-kB activation is dependent upon CYLD
expression.
E6 Reduces CYLD Expression through
a Proteasome-Dependent Mechanism
Given the established role of E6 in degradation of cellular pro-
teins through K48 polyubiquitination, we postulated that if
CYLD were the molecular target of E6, then an inverse correla-
tion between E6 and CYLD protein levels should exist. In HeLa
and SiHa cells in which E6 protein levels were reduced by
RNAi, the corresponding CYLD levels increased (Figure 5A). In
contrast, E6 siRNA had no effect on CYLD levels in DLD-1 cells
(Figure 5A). Transient transfection studies involving E6 and
FLAG-tagged CYLD constructs in HEK293 cells demonstrated
that CYLD expression was reduced by E6 in a dose-dependent
manner (Figure 5B). Ectopic expression of E6 also decreased en-
dogenous CYLD levels in HEK293 cells (Figure 5B, compare
rightmost two lanes). Importantly, degradation of CYLD by E6
was prevented by treatment of cells with the proteasome inhib-
itor MG-132 (Figure 5C). Based on these results, we concluded
that E6 targets CYLD for proteasome-mediated degradation.
To further define the relationship between E6 and CYLD, we
tested whether E6 expression is associated with CYLD polyubi-
quitination. FLAG-CYLD was cotransfected with HA-tagged
ubiquitin and increasing amounts of E6 into HEK293 cells treated
with MG-132 prior to harvesting protein to prevent CYLD degra-
dation. FLAG-CYLD was immunoprecipitated, and polyubiquiti-
nation of CYLD was analyzed by immunoblotting with an anti-
ubiquitin antibody. As shown in Figure 5D, the degree of
FLAG-CYLD polyubiquitination correlated with the amount of
transfected E6. These findings further establish CYLD as a mo-
lecular target of E6.400 Cancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier IncHypoxia-Induced Degradation of CYLD Is Associated
with E6-Mediated CYLD Ubiquitination
Because E6 effects on NF-kB are predominantly observed under
hypoxic conditions, we reasoned that CYLD expression should
be modulated by hypoxia in HPV-positive cells, whereby hypoxia
would lead to decreased CYLD expression and consequent dis-
inhibition of the NF-kB pathway. Indeed, hypoxia led to a rapid
and prolonged decrease in CYLD protein levels in both HeLa
and SiHa cells, which was abrogated by proteasome inhibition
(Figure 6A). The suppression of CYLD protein levels during hyp-
oxia-induced NF-kB activation is particularly noteworthy be-
cause NF-kB has been shown to transcriptionally activate the
CYLD gene (Jono et al., 2004). In contrast to HPV-positive cells,
CYLD protein levels were unaffected by hypoxia in HPV-negative
cell lines (Figure 6B).
Next, we studied the ubiquitination status of CYLD under hyp-
oxic conditions. Exposure of HPV-positive cells to hypoxia led to
a marked increase in ubiquitinated CYLD (Figure 6C, compare
Figure 5. E6 Reduces CYLD Expression through a Proteasome-
Dependent Mechanism
(A) Western blots for CYLD expression in cells transfected with control or E6
siRNA.
(B) CYLD expression in cells transfected with the indicated combinations of
HPV16 E6 or FLAG-tagged CYLD.
(C) Same as in (B), except that cells were treated with the proteasome inhibitor
MG-132 (10 mM) for 2 hr prior to harvesting protein.
(D) Ubiquitination of CYLD in the presence of E6. Cells were exposed to MG-
132 (10 mM) for 2 hr prior to harvesting protein. IP, immunoprecipitation; IB, im-
munoblot. Ubiquitination assays were performed under denaturing conditions..
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statusofCYLDwasunaffectedbyhypoxia inC33Acells (Figure6C,
compare lane 10 and lane 12). We then tested whether hypoxia-
induced CYLD ubiquitination was dependent upon expression
of E6. For these studies, we studied the state of CYLD ubiquitina-
tion in SiHa and HeLa cells that were treated with E6-specific
siRNA or control siRNA. As expected, silencing of E6 expression
(but not control siRNA) abrogated hypoxia-induced CYLD ubiqui-
tination (Figure 6D). These results indicate that CYLD ubiquitina-
tion is enhanced under hypoxia in an E6-dependent fashion.
CYLD-mediated inactivation of the NF-kB pathway occurs
through K63 deubiquitination of TRAFs (e.g., TRAF2 and
TRAF6) as well as IKKg, the latter of which is required for IKKb
kinase activity. As such, we reasoned that IKKb kinase activity
should be inversely related to CYLD protein levels. That is, as
cellular levels of CYLD and its associated NF-kB-inhibitory ef-
fects decline under hypoxic conditions, IKKb activity would be
expected to increase. Indeed, in both HeLa and SiHa cells, hyp-
Figure 6. Effects of Hypoxia and Hydroxyl-
ation Inhibition on CYLD Expression and
Ubiquitination
(A) Top two rows: western blots for CYLD and actin
after cells were exposed to hypoxia for the indi-
cated times. Bottom row: Same as in top rows,
except that cells were treated with MG-132 for
2 hr prior to protein extraction.
(B) CYLD and actin western blots of protein har-
vested from the indicated HPV-negative cells ex-
posed to hypoxia.
(C) CYLD ubiquitination status under normoxia,
under hypoxia, and upon inhibition of hydroxylase
activity with dimethyloxalylglycine (DMOG). Cells
were exposed to hypoxia or DMOG for 6 hr in the
presence of MG-132 (10 mM) to prevent CYLD
degradation. Protein was immunoprecipitated
with an anti-CYLD antibody or IgG isotype control
and then subjected to immunoblotting with the in-
dicated antibodies. The bottom panels demon-
strate equivalent input of CYLD into all lanes.
(D) Effects of E6 gene silencing on hypoxia-in-
duced CYLD ubiquitination. Cells were transfected
with E6-specific or control siRNA and, after 24 hr,
exposed to normoxia or hypoxia for an additional 6
hr. Coimmunoprecipitation to assess CYLD ubiq-
uitination was performed as in (C). The bottom
panels demonstrate effective silencing of E6 pro-
tein expression. (Current antibodies cannot detect
E6 by direct immunoblotting, so E6 immunopre-
cipitation followed by E6 immunoblotting with
two different E6 antibodies was performed.)
oxia-induced CYLD repression was tem-
porally associated with activation of
IKKb, and treatment of cells with a protea-
some inhibitor not only prevented the de-
cline in CYLD levels but also inhibited the
IKKb activation observed during hypoxia
(Figure S6).
In addition to its deubiquitination ef-
fects on TRAFs and IKKg, CYLD also
deubiquitinates Bcl-3, and in so doing
prevents its nuclear localization (Massoumi et al., 2006). Bcl-3
is a transcriptional coactivator that, when recruited to p50 homo-
dimers, activates the transcriptional properties of DNA-bound
p50 (Watanabe et al., 1997; Fujita et al., 1993). Because p50
lacks a transactivation domain, p50 homodimers will not induce
gene transcription in the absence of bound Bcl-3. Given that p50
homodimers form in response to hypoxia (see Figure 1C), we hy-
pothesized that as CYLD levels decrease under hypoxic condi-
tions, Bcl-3 should increasingly accumulate in the nucleus. In
fact, nuclear Bcl-3 levels increased in a time-dependent fashion
under hypoxic conditions (Figure S7), a finding that further impli-
cates a central role for CYLD in the development of hypoxia-
induced NF-kB activation.
Hypoxia Leads to Enhanced E6-CYLD
Protein-Protein Interactions
Our results so far suggest a model in which E6, in its capacity to
function as part of an E3 ubiquitin ligase complex, ubiquitinatesCancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc. 401
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thereby extinguishing the inhibitory effects of CYLD on the
NF-kB pathway and leading to heightened NF-kB activation
(see schematic in Figure 7A). To gain more insight into the differ-
ential effects of E6 on CYLD in normoxia versus hypoxia, we
considered that the biochemical effects of hypoxia are
frequently mediated by altered protein-protein interactions.
Indeed, posttranslational hydroxylation mediated by cellular hy-
droxylases can enhance or diminish protein-protein interac-
tions. For example, asparagine hydroxylation of the transactiva-
tion domain of HIFa by an asparaginyl hydroxylase known as
factor inhibitor of HIF (FIH) prevents the recruitment of the tran-
scriptional coactivator CBP/p300 (Lando et al., 2002), yet prolyl
hydroxylation by prolyl hydroxylases enhances the HIFa interac-
tion with the von Hippel-Lindau ubiquitin ligase complex (Hirota
and Semenza, 2005). Thus, we postulated that hypoxia would
lead to an enhanced protein-protein interaction between E6
and CYLD, thereby allowing for more efficient E6-mediated
ubiquitination.
We performed coimmunoprecipitation studies in HeLa and
SiHa cells to compare the intensity of the putative E6-CYLD pro-
Figure 7. The E6-CYLD Protein-Protein Interaction
Is Enhanced by Hypoxia and Hydroxylase Inhibition
(A) Schematic diagram depicting the mechanism whereby
HPV-encoded E6 activates NF-kB through ubiquitination
and subsequent proteasomal degradation of CYLD.
(B) Protein extracts were exposed to normoxia, hypoxia, or
DMOG for 6 hr in the presence of MG-132 (10 mM) and then
subjected to coimmunoprecipitation studies to evaluate
E6-CYLD protein-protein interactions (top rows). E6-p53
coimmunoprecipitations are shown in the middle rows. Immu-
noprecipitations with an isotype control antibody are shown in
lanes 1 and 5.
(C) CYLD does not immunoprecipitate with AKT. Experiments
were performed as in (B) with the indicated antibodies. For (B)
and (C), the protein extracts were the same as those employed
for Figure 6.
(D) CYLD protein expression was assessed in cells treated
with vehicle (DMSO) or DMOG.
tein-protein interaction in normoxia versus hyp-
oxia. HeLa and SiHa cells were exposed to MG-
132 (10 mM) for 1 hr prior to harvesting protein in
order to prevent E6-mediated, proteasome-de-
pendent degradation of CYLD. Indeed, these im-
munoprecipitation studies demonstrated that E6
and CYLD interact weakly in SiHa and HeLa cells
under normoxia (Figure 7B, lanes 2 and 6). Impor-
tantly, the interaction was markedly augmented by
hypoxia (Figure 7B, compare lanes 2–4 and lanes
6–8). As a positive control, we coimmunoprecipi-
tated p53 with the E6 antibody (Figure 7B). The
specificity of the interaction was established
through pull-downs with an isotype control anti-
body (Figure 7B, lanes 1 and 5) as well as an
anti-AKT antibody (Figure 7C, lanes 1, 2, 4, 6, 7,
and 9), neither of which revealed CYLD in the im-
munoprecipitate. These results support the notion
that the E6-dependent effects on CYLD are medi-
ated through protein-protein interactions that are enhanced dur-
ing hypoxia.
HPV E6-mediated degradation of p53 is dependent upon E6-
AP, which in conjunction with E6 forms a ternary complex with
p53, thereby leading to polyubiquitination and proteasome-de-
pendent degradation of p53 (Scheffner et al., 1990, 1993; Hui-
bregtse et al., 1991). Many other E6-AP-dependent targets of
E6, such as ErbB2, have been reported (Narisawa-Saito et al.,
2007). Given the established role of E6-AP in mediating many
E6 effects, we explored the role of E6-AP in E6-dependent, hyp-
oxia-induced NF-kB activation. Toward this end, we introduced
lentiviral constructs expressing E6-AP-specific short hairpin
RNA (shRNA) or scrambled control shRNA into HeLa and SiHa
cells. Functional knockdown of E6-AP was demonstrated by res-
toration of p53 expression in E6-AP shRNA-expressing cells
(Figure S8A). Silencing of E6-AP did not influence hypoxia-in-
duced effects on CYLD expression, IKKb kinase activity, or
NF-kB EMSAs (Figures S8B–S8D). Similar findings were found
with two other E6-AP shRNAs (data not shown). These results in-
dicate that E6-AP is not involved in E6-dependent, hypoxia-
induced effects on the NF-kB pathway.402 Cancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc.
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Are Recapitulated by Hydroxylase Inhibition
To begin to explore the biochemical effects that mediate
suppression of CYLD expression in hypoxia, we considered
that hypoxia-induced posttranslational effects are frequently
mediated by oxygen-dependent prolyl or asparaginyl hydrox-
ylases (Schofield and Ratcliffe, 2005). Because the effects of
E6 on CYLD are more pronounced under hypoxic conditions,
we postulated that reduced activity of oxygen-dependent
hydroxylases that results when molecular oxygen is a
limiting substrate enhances the E6-mediated effects on
CYLD. Accordingly, we determined whether treatment of
HeLa and SiHa cells with the pan-hydroxylase inhibitor dime-
thyloxalylglycine (DMOG) would recapitulate the effects of
hypoxia. DMOG treatment (but not vehicle control) led to
a drop in CYLD protein levels (Figure 7D). Hydroxylase inhibi-
tion also resulted in heightened CYLD ubiquitination and
enhanced the protein-protein interaction between E6 and
CYLD (Figure 6C, compare lane 2 to lane 3 and lane 6 to
lane 7; Figure 7B, compare lane 2 to lane 3 and lane 6 to lane
7; Figure 7C). The E6 dependence of this effect was high-
lighted by the fact that DMOG failed to induce CYLD ubiquiti-
nation in HPV-negative cells (Figure 6C, compare lane 10 to
lane 11). These findings implicate a role for hydroxylation as a
posttranslational modification that mediates the effects of E6 on
CYLD.
NF-kB Activation Is Required for Anchorage-
Independent Growth under Hypoxic Conditions
in HPV-Positive Cells
To establish a biologic role for hypoxia-induced NF-kB activa-
tion in HPV-positive squamous cell carcinomas, we deter-
mined whether NF-kB activation was necessary for anchor-
age-independent growth. SiHa and HeLa cells were
transduced with an adenoviral vector containing an IkB ‘‘super
repressor’’ (IkB-SR), in which serine phosphorylation sites are
mutated to alanines, rendering the IkB-SR resistant to protea-
some-mediated degradation (Karin, 2006). Ectopic expression
of the IkB-SR effectively inhibited hypoxia-induced NF-kB ac-
tivation in SiHa and HeLa cells (Figure 8A). Both the size and
number of SiHa and HeLa colonies transduced with a control
adenovirus actually increased in hypoxic compared to nor-
moxic conditions (Figure 8B). Importantly, this effect was com-
pletely abolished by expression of the IkB-SR (Figure 8B),
a finding that confirms that heightened NF-kB activation due
to hypoxia exposure is critical to anchorage-independent
growth of HPV-positive squamous cell carcinomas. Next, we
assessed whether CYLD suppresses hypoxia-induced anchor-
age-independent growth. HeLa cells were transfected with
a plasmid encoding wild-type CYLD or a CYLD mutant (C/S-
CYLD) in which its enzymatic activity is abolished by an amino
acid substitution in the cysteine box of the deubiquitinase
domain (Brummelkamp et al., 2003). Compared to transfec-
tion with an empty vector control, wild-type CYLD transfec-
tion reduced hypoxia-induced colony formation, whereas the
C/S-CYLD mutant did not (Figure 8C), a finding indicating
that CYLD inhibits hypoxia-induced anchorage-independent
growth.CDISCUSSION
HPV is an established carcinogen in humans. Abundant epidemi-
ologic and experimental evidence has led to the recognition of
HPV as a causative agent in 90%–98% of cases of squamous
cell carcinoma of the cervix (Psyrri and DiMaio, 2008), the sec-
ond most common cancer in women worldwide, with an annual
incidence and mortality of 500,000 and 200,000, respectively (El-
lenson and Wu, 2004; Waggoner, 2003). HPV types 16 and 18
account for approximately 70% of cervical cancer cases (Psyrri
and DiMaio, 2008), with other high-risk types accounting for the
majority of the remaining cases. Moreover, HPV infection is
thought to be causally related to other squamous cell carcino-
mas, including vulvar, anal, penile, and oropharyngeal cancers
(Psyrri and DiMaio, 2008).
In HPV-associated cancer, HPV DNA is typically integrated
into the cellular genomic DNA, and most of the viral genome is
deleted except for the E6 and E7 genes (Psyrri and DiMaio,
2008). E7 is known for its ability to bind to and inhibit pRB func-
tion, whereas E6 is most notorious for its role in ubiquitination
and degradation of p53 (Narisawa-Saito et al., 2007). However,
p53-independent functions of E6 are well described, and, in
fact, p53 elimination is not required for cellular immortalization
by E6 (Kiyono et al., 1998). For example, E6 mediates the degra-
dation of the proapoptotic protein BAK and the TSC1 tumor sup-
pressor and activates cellular telomerase (Klingelhutz et al.,
1996; Narisawa-Saito et al., 2007). Here, we describe a role for
the HPV-encoded E6 protein in a biochemical response to hyp-
oxia. Specifically, through its ability to induce sustained NF-kB
activation in response to reduced ambient oxygen tension, E6
mediates a cellular adaptation to prolonged hypoxia. Impor-
tantly, we found that prolonged hypoxia-induced NF-kB activa-
tion is not a generalized phenomenon among cancers but rather
is limited to cancer cells that are infected with high-risk HPV. The
mechanism underlying hypoxia-induced NF-kB activation in-
volves E6-mediated ubiquitination and degradation of the
CYLD K63 deubiquitinase, which releases components in the
NF-kB signaling cascade from the inhibitory effects of CYLD. Al-
though the E6-mediated effects on CYLD and the NF-kB path-
way are intensified under hypoxic conditions, we consistently
observed similar but less pronounced effects in normoxia (Fig-
ures 2B and 2I). Thus, in ambient oxygen tension, E6 gene silenc-
ing in HPV-positive cells led to NF-kB and IKKb activation and in-
creased CYLD expression, whereas ectopic expression of E6 in
HPV-negative cells resulted in NF-kB activation and CYLD deg-
radation. These latter effects are consistent with the results of
the protein-protein interaction studies, which demonstrated
that E6 does in fact bind to CYLD under normoxic conditions, al-
beit to a lesser degree than under hypoxia.
The heightened ubiquitination and degradation of CYLD are
recapitulated by hydroxylase inhibition, which suggests that
posttranslational hydroxylation plays a central role in E6-depen-
dent, hypoxia-induced CYLD degradation. In a preliminary anal-
ysis of the CYLD primary amino acid sequence, we did not de-
tect any consensus prolyl hydroxylation sites (LXXLAP). CYLD
does harbor a potential asparagine hydroxylation site, wherein
the asparagine at position 646 is preceded by valine (position
643) in the context of one or more leucines located seven to eight
positions amino-terminal to the asparagine (Cockman et al.,ancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc. 403
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optimal substrate recognition by the asparaginyl hydroxylase
FIH (Linke et al., 2004). However, these amino acids are not
found within an ankyrin repeat domain, which is the basis for
substrate recognition by FIH (Cockman et al., 2006). Similarly,
the E6 sequence does not contain either prolyl or asparaginyl hy-
droxylation sites. Thus, the details of hypoxia-mediated post-
translational regulation of the E6-CYLD interaction remain to
be elucidated and may involve a previously unidentified oxy-
gen-sensing hydroxylase. It is also plausible that posttransla-
tional hydroxylation may take place in a protein involved in for-
mation of a protein complex that includes E6 and CYLD,
Figure 8. Hypoxia-Induced Enhancement of
Anchorage-Independent Growth Is NF-kB
Dependent
(A) EMSAs and reporter assays to define the mul-
tiplicity of infection (moi) of an adenoviral vector
containing an IkB ‘‘super repressor’’ (Ad-IkB-SR)
that blocks hypoxia-induced NF-kB activity.
EMSAs were performed after 24 hr of hypoxia ex-
posure, and reporter activity was assayed after
48 hr of hypoxia. The reporter results are the
means of three experiments ± SD.
(B) Results of anchorage-independent growth as-
says from all groups at 14 days were normalized to
those of the normoxic group transduced with con-
trol virus (Ad-CMV). Representative phase-con-
trast photomicrographs are shown at lower right
(final magnification = 2003).
(C) Anchorage-independent growth of HeLa cells
transfected with the indicated plasmids (vector
control, wild-type CYLD, or C/S-CYLD mutant) un-
der G418 selection. Results in (B) and (C) repre-
sent the mean number of colonies counted per
field (2003 magnification; five fields counted per
group) ± SD.
(D) Model of cellular NF-kB responses to hypoxia
(see Discussion for details).
whereby hydroxylation impairs complex
formation and, by extension, the ability
of E6 to target CYLD for ubiquitination.
Interactions between p53 and NF-kB
have been reported. On the one hand,
mutual transcriptional repression has
been reported between p53 and NF-kB,
yet p53 has also been shown to activate
NF-kB in some contexts (Ikeda et al.,
2000; Wadgaonkar et al., 1999; Webster
and Perkins, 1999; Huang et al., 2007;
Ryan et al., 2000). Thus, in the interpreta-
tion of the experiments involving E6 RNAi,
we considered that the inhibition of con-
stitutive and hypoxia-induced NF-kB
through suppression of endogenous E6
protein could potentially be attributed to
p53-dependent effects on NF-kB. Specif-
ically, restoration of p53 expression by E6
RNAi could result in reduced NF-kB tran-
scriptional activity if mutual transcrip-
tional repression between p53 and NF-kB were operative in
HPV-positive cells. However, it has recently been shown that in
models in which p53 suppresses NF-kB transcriptional activity,
NF-kB DNA binding is actually enhanced and DNA-bound
NF-kB undergoes p53-dependent posttranslational modifica-
tions that result in transcriptional inhibition of NF-kB (Kawauchi
et al., 2008). Yet we observed decreased NF-kB DNA binding in
response to E6 RNAi in HPV-positive cells (Figure 2B;
Figure S3B). Moreover, since p53-dependent transcriptional inhi-
bition of NF-kB does not appear to involve TRAF6 or CYLD (Ikeda
et al., 2000; Wadgaonkar et al., 1999) and since p53 expression
remains undetectable under hypoxic conditions due to the404 Cancer Cell 14, 394–407, November 4, 2008 ª2008 Elsevier Inc.
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hypoxia-induced NF-kB activation in HPV-positive cells.
In addition to the prolonged hypoxia-induced NF-kB activation
observed in HPV-positive cells, we observed that some HPV-
negative tumor models are capable of transient NF-kB activation
during hypoxia (Figure 1F; Figure S2B). A mechanism for E6-in-
dependent NF-kB activation is suggested by a recent report in
which IKKb was shown to be negatively regulated by prolyl hy-
droxylase-1 (PHD-1), such that under conditions in which oxy-
gen is a limiting substrate (i.e., hypoxia), PHD-1 activity is dimin-
ished and IKKb activity is augmented (Cummins et al., 2006). To
account for the varied hypoxia-induced NF-kB responses that
we observed, we propose the following model (illustrated in
Figure 8D). In what we term type I cells, HPV infection and
more specifically the E6 protein, perhaps in conjunction with
a hydroxylase and other cellular proteins, result in prolonged
hypoxia-induced NF-kB activation. Type II cells are HPV nega-
tive and manifest transient hypoxia-induced NF-kB activation
mediated by hydroxylases (e.g., PHD-1) and possibly other cel-
lular factors. In type III cells, which are also HPV negative, either
augmentation of NF-kB activity is entirely prevented or hypoxia
induces a decrease in NF-kB activity. Because the tumor micro-
environment is typified by chronic hypoxia, the prolonged nature
of the NF-kB activation observed in the setting of HPV infection
may represent a more suitable adaptive response to hypoxia
in vivo.
The clinical evidence that hypoxia is associated with poor out-
comes (e.g., increased local tumor recurrence, development of
systemic metastases, resistance to radiation and chemother-
apy, and reduced overall survival) has been best established in
two HPV-associated cancers, cervical and head and neck can-
cers, although ample clinical data also exist for sarcomas (Sub-
arsky and Hill, 2003). Importantly, frequent NF-kB activation has
been observed in cervical and head and neck patient specimens
(Mishra et al., 2006; Nair et al., 2003). A recent study highlights
the HPV-NF-kB connection: the degree of NF-kB activation
was reported to correlate with HPV status in head and neck can-
cer (Mishra et al., 2006). A biological role for hypoxia-induced
NF-kB activation is supported by our studies demonstrating
that HPV-positive cervical cancer cells are dependent upon
heightened NF-kB activity for optimal anchorage-independent
growth under hypoxic conditions. Since NF-kB transcriptional
activity results in expression of proteins that promote angiogen-
esis, proliferation, drug resistance, invasion, and metastasis, the
aggressive tumor biology characteristic of hypoxic tumors could
in large part be recapitulated by hypoxia-induced NF-kB activa-
tion. However, NF-kB transcriptional activity cannot account for
the entire hypoxic gene expression profile, and other transcrip-
tion factors, such as HIFa, are known to play a central role in cel-
lular responses to hypoxia (Denko et al., 2003). Nevertheless,
prolonged hypoxia-induced NF-kB activation is apt to promote
tumor progression in HPV-infected malignancies and has impor-
tant implications for the carcinogenesis and potential therapeu-
tic targeting of the relatively common malignancies associated
with HPV infection.
EXPERIMENTAL PROCEDURES
Detailed methods are presented in Supplemental Experimental Procedures.CIn Vitro Hypoxia Treatment
All hypoxia experiments were carried out in 1% oxygen (O2) in a chamber in
which CO2 and nitrogen were independently regulated (BioSpherix). Oxygen
and CO2 concentrations were continuously monitored with probes residing
within the chamber. Calibration of the oxygen probe to ambient oxygen con-
centrations (21% O2) and 0% oxygen (100% nitrogen) was performed period-
ically. For protein extractions, cells were removed from the hypoxia chamber,
medium was rapidly aspirated, and ice-cold phosphate-buffered saline was
immediately added for washing.
In Vivo Hypoxia
All animal studies were performed in accordance with institutional and national
guidelines and were approved by the Animal Research Committee of the VA
Greater Los Angeles Healthcare System–West Los Angeles. HeLa or CAL27
cells (2 3 106 cells in 200 ml of saline) were injected subcutaneously into the
right flank of 6-week-old female nude mice. Tumors were grown until a maxi-
mum diameter of 1 cm was reached. Sixty minutes prior to euthanasia, mice
were injected intraperitoneally with 1 mg/kg of pimonidazole (NPI, Inc.), a 2-ni-
troimidazole that forms adducts with thiol groups on cellular proteins and pep-
tides at a partial pressure of oxygen (pO2) < 10 mm Hg.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, one table, and eight figures and can be found
with this article online at http://www.cancercell.org/supplemental/S1535-
6108(08)00331-0.
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